At the news
? NEUTRALIMPACT 4/10 EFFECT filed Nov 5, 2026 at 00:15 ET
Fulcrum Therapeutics received SEC effectiveness for its S-4 registration statement (File No. 333-298705) on November 4, 2026. This allows the company to proceed with the business combination or exchange offer described in the S-4, typically a merger or acquisition involving stock consideration.
- EFFECT notice filed November 5, 2026, with effectiveness date of November 4, 2026
- Registration statement on Form S-4 (File No. 333-298705) declared effective
- S-4 is used for business combinations, exchange offers, or reclassifications involving stock
- Fulcrum Therapeutics is a pharmaceutical company with $279M market cap
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access